KKR’s deal is a bet that financing needs from drug companies will continue to rise. - Michael Nagle/Bloomberg News. KKR has ...

Investment firm KKR (KKR) announced on Wednesday the acquisition of a majority stake in the biopharma royalty acquisition company, HealthCare Royalty Partners.

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

OrbiMed, a leading global healthcare investment firm, today announced it has raised $1.86 billion in commitments for OrbiMed Royalty and Credit Opportunities Fund V.

NEW YORK (Reuters) -Investment giant KKR reported a 9% rise in adjusted net income for the second quarter on Thursday, ...

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

The firm brought in $1.6 billion from outside investors for its fifth main growth fund and separately promoted dealmaker Sri Rao. The credit-card company reported increases in profit and sales in the ...

KKR continues its aggressive transformation from traditional private equity into a diversified financial powerhouse through strategic acquisitions and fund initiatives. The investment giant recently ...

The investment firm acquired a majority stake in HealthCare Royalty Partners. The firm brought in $1.6 billion from outside investors for its fifth main growth fund and separately promoted dealmaker ...

Q2 2025 Earnings Call Transcript July 31, 2025 KKR & Co. Inc. beats earnings expectations. Reported EPS is $1.18, ...

The IPO market could soon succumb to its typical late-summer slowdown, but don’t be surprised to see more companies looking ...